Epidermal growth factor receptor (EGFR) exon 19 deletion (Ex19del) is one of the most prevalent sensitizing mutations in non-small cell lung cancer (NSCLC), Introduction Non-small-cell lung cancer (NSCLC) is a common malignancy worldwide, with adenocarcinoma as the predominant subtype (1,...
AbstractBackground Epidermal growth factor (EGF) and its receptor EGF(EGFR) play crucial roles in glioblastoma (GBM) prognosis. However, non-invasive assessment of their expression remains challenging. This study aimed to determine whether radiomics features extracted from contrast-enhanced MRI could predict EGFR expression...
Abstract Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been standard of care as monotherapy for EGFR-mutated advanced non-small cell lung cancer since reporting of the FLAURA phase III clinical trial, which demonstrated superiority over first-generation...
EGFR Signaling Linked to Oral Cancer Pain and Reduced Opioid Effectiveness Researchers have identified a shared biological process involving epidermal growth factor receptor (EGFR) signaling that contributes to both oral cancer pain and reduced effectiveness of opioid medications. The study...
BackgroundEpidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are typically considered mutually exclusive i 1 Introduction Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide. With the advent of precision oncology, EGFR mutations...
ObjectivesEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are established first-line treatments for advanced non-small cell lung ca Introduction Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 75-85% of...
AbstractPurpose Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used as the standard-of-care first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, EGFR-TKI resistance has become a major challenge for almost all patients with EGFR-mutated...
